The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection

MmpL3 is a protein that is required for the survival of bacteria that cause tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. This report describes the discovery and characterization of a new small molecule, MSU-43085, that targets MmpL3 and is a potent inhibitor of (Mtb) and surv...

Full description

Saved in:
Bibliographic Details
Published in:Microbiology spectrum 2024-01, Vol.12 (1), p.e0367723
Main Authors: Williams, John T, Giletto, Matthew, Haiderer, Elizabeth R, Aleiwi, Bilal, Krieger-Burke, Teresa, Ellsworth, Edmund, Abramovitch, Robert B
Format: Article
Language:English
Subjects:
Animals
Antimicrobial Chemotherapy
drug development
Mice
MmpL3
Mycobacterium Infections, Nontuberculous - microbiology
Mycobacterium tuberculosis
Nontuberculous Mycobacteria
Research Article
Tuberculosis - drug therapy
Tuberculosis - microbiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MmpL3 is a protein that is required for the survival of bacteria that cause tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. This report describes the discovery and characterization of a new small molecule, MSU-43085, that targets MmpL3 and is a potent inhibitor of (Mtb) and survival. MSU-43085 is shown to be orally bioavailable and efficacious in an acute model of Mtb infection. However, the analog is inactive against Mtb in chronically infected mice. Pharmacokinetic and metabolite identification studies identified metabolism of MSU-43085, leading to a short half-life in treated mice. These proof-of-concept studies will guide further development of the MSU-43085 series for the treatment of TB or NTM infections.
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.03677-23